COVID-19 Laboratory Codes (UB04 Billing)
<p>Blue Cross and Blue Shield of Kansas (BCBSKS) continues to monitor COVID-19 and the changes with billing new codes. The following new codes will be reimbursed as follows:</p>
<table>
<tbody>
<tr>
<td>
<p><strong>CPT Code</strong></p>
</td>
<td>
<p><strong>Nomenclature</strong></p>
</td>
<td>
<p><strong>MAP'd like:</strong></p>
</td>
</tr>
<tr>
<td>
<p>0225U</p>
</td>
<td>
<p>INFECTIOUS DISEASE (BACTERIAL OR VIRAL RESPIRATORY TRACT INFECTION) PATHOGEN-SPECIFIC DNA AND RNA, 21 TARGETS, INCLUDING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2), AMPLIFIED PROBE TECHNIQUE, INCLUDING MULTIPLEX REVERSE TRANSCRIPTION FOR RNA TARGETS, EACH ANALYTE REPORTED AS DETECTED OR NOT DETECTED</p>
</td>
<td>
<p>0202U</p>
</td>
</tr>
<tr>
<td>
<p>0226U</p>
</td>
<td>
<p>SURROGATE VIRAL NEUTRALIZATION TEST (SVNT), SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]), ELISA, PLASMA, SERUM</p>
</td>
<td>
<p>86382</p>
</td>
</tr>
<tr>
<td>
<p>86408</p>
</td>
<td>
<p>NEUTRALIZING ANTIBODY, SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]); SCREEN</p>
</td>
<td>
<p>86769</p>
</td>
</tr>
<tr>
<td>
<p>86409</p>
</td>
<td>
<p>NEUTRALIZING ANTIBODY, SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) (CORONAVIRUS DISEASE [COVID-19]); TITER</p>
</td>
<td>
<p>0224U</p>
</td>
</tr>
</tbody>
</table>
<p> </p>
<p>If you have any questions regarding this newsletter, please contact your <a href="/providers/institutional/contact-us">BCBSKS Institutional Relations provider consultant</a>.</p>